Alleviation of Pulmonary Fibrosis by the Dual PPAR Agonist Saroglitazar and Breast Milk Mesenchymal Stem Cells via Modulating TGFß/SMAD Pathway

Researchers investigated the potential roles of saroglitazar and/or breast milk mesenchymal stem cells in pumonary fibrosis and to spot their underlying protective mechanisms.